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Abstract
In order to determine the effect of ursodeoxycholic acid on nonalco-
holic fatty liver disease, 30 patients with body mass indices higher
than 25, serum levels of alanine aminotransferase (ALT), aspartate
aminotransferase (AST) or γ-glutamyltransferase (γ-GT) at least more
than 1.5 times the upper limit of normality, and hepatic steatosis
demonstrated by ultrasonography were randomized into two groups of
15 patients to receive placebo or 10 mg kg-1 day-1 ursodeoxycholic acid
for three months. Abdominal computed tomography was performed to
quantify hepatic fat content, which was significantly correlated with
histological grading of steatosis (rs = -0.83, P < 0.01). Patient body
mass index remained stable for both groups throughout the study, but
a significant reduction in mean (± SEM) serum levels of ALT, AST
and γ-GT was observed only in the treated group (ALT = 81.2 ± 9.7,
44.8 ± 7.7, 48.1 ± 7.7 and 52.2 ± 6.3 IU/l at the beginning and after the
first, second and third months, respectively, N = 14, P < 0.05). For the
placebo group ALT values were 66.4 ± 9.8, 54.5 ± 7, 60 ± 7.6 and 43.7
± 5 IU/l, respectively. No alterations in hepatic lipid content were
observed in these patients by computed tomography examination
(50.2 ± 4.2 Hounsfield units (HU) at the beginning versus 51.1 ± 4.1
HU at the third month). These results show that ursodeoxycholic acid
is able to reduce serum levels of hepatic enzymes in patients with
nonalcoholic fatty liver disease, but this effect is not related to
modifications in liver fat content.
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Introduction
Nonalcoholic fatty liver disease (NAFLD)
has been diagnosed with a higher frequency
in the last years because of improved imag-
ing methods. Most patients are asymptomat-
ic and show no signs of disease (1,2). Serum
levels of hepatic enzymes (mainly ami-
notransferases and γ-glutamyltransferase,
γ-GT) may or may not be increased. Hepatic
ultrasound, computed tomography (CT) and
magnetic resonance imaging (MRI) have
good sensitivity and specificity for the diag-
nosis of hepatic steatosis, but only CT and
MRI are considered to be reliable methods
for the grading of liver fat content (3,4).
724
Braz J Med Biol Res 36(6) 2003
V.N. Santos et al.
In spite of the high prevalence of hepatic
steatosis and of the potential of nonalcoholic
steatohepatitis (NASH) to progress to fibro-
sis and cirrhosis, no effective specific treat-
ment is available. The procedure used today
is based only on the removal of the possible
causal factors (5,6).
During the last few years ursodeoxycholic
acid (UDCA) has been used to treat many
diseases of the liver, such as hepatic chole-
static diseases and chronic hepatitis, among
others (7-10). In uncontrolled studies, UDCA
was used to treat NASH, with biochemical
improvement of hepatic enzymes and of the
inflammatory activity of the liver (11,12).
In the present study we determined the
effects of the administration of UDCA for
three months on the serum levels of hepatic
enzymes and on liver lipid content evaluated
by CT and MRI in patients with NAFLD
secondary to nonpathological obesity.
Patients and Methods
Patients with persistent abnormal levels
of biochemical markers for more than six
months, with a body mass index (BMI) higher
than 25, alanine aminotransferase (ALT),
aspartate aminotransferase (AST) or γ-GT
levels at least more than 1.5 times the upper
limit of normality, and ultrasonography show-
ing signs of hepatic steatosis were enrolled
in the study. Patients drinking more than 40
g ethanol per week, with decompensated
diabetes mellitus, serum cholesterol and tri-
glycerides above 300 mg/dl, continuous in-
take of hepatotoxic medicines, positive hepa-
titis B surface antigen (HBsAg) and anti-
hepatitis C virus (HCV) antibodies or other
concomitant hepatic or recognized systemic
diseases were excluded from the study.
Before the beginning of therapy and every
month up to the end of treatment, patient
BMI was calculated by the Quetelet method
(13). All patients were tested for serum lev-
els of ALT, AST, γ-GT, total cholesterol and
triglycerides, thyroid-stimulating hormone,
free T4 and glucose, HBsAg, and anti-HBc
and anti-HCV antibodies (ELISA, Abbott
Laboratories, North Chicago, IL, USA). MRI
was performed with a Gyroscan S15 appara-
tus at 1.5 Tesla (Philips, Eindhoven, The
Netherlands) and the Somaton DR scanner
equipment (Siemens, Erlangen, Germany)
was used for hepatic CT. Unenhanced scans
were obtained at 125 kVp, 230 mAs. Images
were obtained using 8-mm collimation and
12-mm increment. Liver attenuation values
were obtained using a 2-cm diameter circu-
lar region of interest, with the cursor placed
at approximately the same site in each he-
patic segment, avoiding artifacts or vessels.
Attenuation measurements of the spleen were
also made and the liver-to-spleen attenua-
tion difference was calculated. Since CT
studies could not be performed in patients
with a body weight of more than 120 kg,
seven patients were not evaluated (three in
the treated group and four in the placebo
group).
Liver biopsy specimens were obtained
by percutaneous puncture with Tru-Cut
needles from all patients before starting treat-
ment. Specimens were fixed in neutral buff-
ered formalin, embedded in paraffin and
stained with hematoxylin-eosin, Masson’s
trichrome and Perls’ Prussian blue. The his-
topathological lesions were assessed and
scored according to the degree of fat accu-
mulation, portal and parenchymal inflam-
mation, fibrosis, and ballooning degenera-
tion. Macrovesicular steatosis was graded
0-3 based on the percentage of involved
hepatocytes in the biopsy specimens (1: up
to 33%; 2: 33 to 66%, and 3: >66%) (14).
NAFLD was classified into four types ac-
cording to Matteoni et al. (1): type 1 - simple
fatty liver, type 2 - fat plus inflammation,
type 3 - fat with ballooning degeneration,
and type 4 - fibrosis at any stage.
Patients were randomized into two groups
of 15 patients to receive UDCA, 10 mg kg-1
day-1 (divided into two daily doses), or a
placebo administered in a double-blind man-
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ner for a period of three months. Monthly
returns were scheduled for clinical and bio-
chemical evaluation and for control of the
use of medication. MRI and CT were per-
formed at the beginning and at the end of the
study.
The Human Studies Committee of the
Federal University of São Paulo approved
the study, and an informed consent was ob-
tained from all patients.
Statistical analysis
Data are reported as means ± SEM. The
clinical, histological and biochemical pre-
treatment findings for the treated and pla-
cebo groups were compared by the unpaired
t-test for continuous variables and by the χ2
test for comparison of frequency data. The
mean values of the variables within the same
group at different times were compared by
analysis of variance for repeated measure-
ments, complemented by the Bonferroni test
for multiple comparisons. The paired t-test
was applied to compare the values of CT
attenuation before and at the end of treat-
ment between control and treated patients.
Spearman’s correlation coefficient was cal-
culated for the relationship between the at-
tenuation values of CT or MRI and the histo-
logical grading of hepatic steatosis (15).
Results
The study groups were comparable re-
garding age, sex, associated factors, BMI,
type of NAFLD and hepatic enzyme serum
levels (Table 1). There was an association of
obesity with dyslipidemia and diabetes in 12
patients.
No correlation was detected between con-
ventional MRI and the histological grading
for steatosis (Figure 1), while CT attenuation
was inversely and significantly correlated
with the degree of fatty liver accumulation
(rs = -0.83, P < 0.01; Figure 2).
During treatment, the patients’ BMI re-
Table 1. Clinical and histological data for UDCA-treated and placebo groups of obese
patients with nonalcoholic fatty liver disease.
UDCA Placebo
Age 38.4 ± 2.1 36.6 ± 3.1
Gender (male/female) 14/1 14/1
Etiology (obesity/dyslipidemia) 15/1 15/4
BMI (up to 29/more than 29) 5/10 7/8
NAFLD (types 1/2/3/4) 6/4/2/3 5/4/3/2
γ-GT (IU/l) 100.7 ± 23.7 97.2 ± 21.9
ALT (IU/l) 79.8 ± 9.21 67.3 ± 9.5
AST (IU/l) 61.9 ± 12.1 40.5 ± 9.9
Data are reported as means ± SEM for 15 patients in each group. ALT and AST: alanine
and aspartate aminotransferase, respectively; BMI: body mass index; γ-GT: γ-glutamyl-
transferase; NAFLD: nonalcoholic fatty liver disease scored as described in Ref. 1;
UDCA: ursodeoxycholic acid. No statistical differences were found for histological or
clinical data between groups.
Figure 1. Correlation between conventional magnetic resonance imaging and the histologi-
cal grading of hepatic steatosis. Fatty liver was graded as described in Ref. 14: +, up to
33%; ++, 33-66%; +++, >66%.
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Figure 2. Correlation between computed tomography attenuation index and the histologi-
cal grading of hepatic steatosis. Fatty liver was graded as described in Ref. 14: +, up to
33%; ++, 33-66%; +++, >66%.
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mained stable (treated group, BMI before vs
end of treatment = 30 ± 0.7 vs 29.8 ± 0.9; P
= 0.893).
Two patients (one from each group) were
excluded because of lack of compliance with
treatment. No patient presented side effects
that could be attributed to the use of UDCA.
In the placebo group no significant modi-
fications in mean AST, ALT or γ-GT values
were observed throughout the study. In con-
trast, a significant reduction in the mean
values for these enzymes was observed in
the UDCA group, especially during the first
two months and also in the third month for
ALT (Figure 3). The response did not differ
in terms of degree of obesity or type of
NAFLD.
No differences were observed between
the values of hepatic density obtained at the
beginning and at the end of the study (treated
group = 50.2 ± 4.2 vs 51.1 ± 4.1; placebo
group = 48.6 ± 5.0 vs 48.1 ± 5.1).
Discussion
It is now clear that the obese patient can
develop NAFLD, with hepatic inflamma-
tion, fibrosis and even cirrhosis (16,17). Ac-
cording to many investigators, fatty liver,
mainly with elevated serum liver enzymes,
can progress to NASH and in some to cirrho-
sis (about 7-26%). NAFLD can be present in
up to 20% of obese patients and in 3 to 4% of
those with normal weight, reaching an over-
all prevalence of 13% (1,14,16-18). Early
studies demonstrated a higher prevalence
among women, related to the higher inci-
dence of obesity in women or secondary to
hormonal effects; however, it is now known
that nonobese men are equally affected
(16,19,20). These differences, however, seem
to depend basically on how the patients are
selected for the study. In the present study,
patients were selected on the basis of abnor-
mal ALT detected during blood donation.
All patients had NAFLD associated with
obesity with or without associated dyslipide-
mia or diabetes. Since these patients had
stable obesity in the last months and were
studied for a short period of time, BMI be-
comes a parameter of easy control to assess
whether modifications in body mass are in-
terfering with the patient’s treatment with
UDCA.
Increases in serum ALT, AST and γ-GT
are frequently observed in NAFLD, although
their levels are often poorly correlated with
histological parameters (1,14,19).
For a proper image analysis, patient
weight was limited to 120 kg since higher
values interfere with the study of the correla-
tion between the degree of obesity and the
intensity of steatosis reported by others
(21,22).
There is evidence of an inverse correla-
tion between CT attenuation in the liver and
the hepatic degree of steatosis (4). Thus, it
has been suggested that CT might provide an
alternative method for quantitatively esti-
mating liver fat content. Absolute liver at-
tenuation values are considered to be of
limited use because they can vary depending
on technical variables like scanner type, tube
current, as well as individual variations in
patient conditions such as cardiac or renal
function (23). We believe that these limita-
tions will be reduced with new generation
scanners.
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Figure 3. γ-Glutamyltransferase (γ-GT), aspartate (AST) and alanine (ALT) aminotransferase
values of the ursodeoxycholic acid (UDCA)-treated and untreated (placebo) patients deter-
mined at the beginning and after the first, second and third month of the experiment. Data
are reported for 14 patients in each group. Error bars were omitted to improve the
understanding of the figure. *P < 0.05 compared to the beginning of the experiment
(Bonferroni test).
***
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MRI has been considered to be the gold
standard for the noninvasive quantification
of fat content in the liver when the technique
of Dixon is used (3,24). In the present study
we found traditional MRI to be less valuable
than CT for the quantification of NAFLD. In
fact, a significant correlation of CT with the
degree of histological steatosis confirmed
results of previous and recently published
studies (4,25).
It has already been stated that the basic
treatment of patients with obesity related to
NAFLD would be weight loss. It is observed,
however, that most of these individuals are
not able to reach this objective in a consist-
ent way, needing a more effective treatment
(5,12,26). In studies of isolated cases (11) or
in uncontrolled studies (12) a histological
and biochemical improvement of NAFLD
was observed after one year of treatment
with UDCA. However, since those were not
controlled studies, and most patients were
obese and were strongly encouraged to lose
weight, it is difficult to attribute the observed
improvements exclusively to the medica-
tion. More recently, it was shown that pa-
tients with NASH (27) and NAFLD (28)
treated with a low fat diet associated with
UDCA presented a more pronounced im-
provement than those treated with diet only.
But again, the effects of UDCA could have
been masked by the diet.
In the present study patients were ran-
domized in a double-blind manner to use
UDCA or placebo for three months based on
studies that showed a significant reduction
or disappearance of steatosis due to nutri-
tional deficiencies during this period of time
(29,30). The daily dose of 10 mg kg-1 day-1
was chosen on the basis of previous studies
with UDCA for the treatment of cholelithi-
asis and hepatic cholestatic diseases (7,8,10,
29), and also because lower doses for obese
patients substantially reduce the cost of treat-
ment.
During treatment, no significant alter-
ations were found in the mean values of
AST, ALT or γ-GT in the control group,
while in the UDCA-treated group a statisti-
cally significant fall in these parameters was
demonstrable during the first two months
and up to the third month for ALT. These
results demonstrate a positive effect of UDCA
by reducing hepatic enzyme levels in pa-
tients with NAFLD, confirming previously
published results (11,12,27,28).
Several reports have confirmed that
UDCA improves the hepatic tests in patients
with chronic hepatic disease (10,26). How-
ever, the exact mechanism of this action is
not understood. The drug may alter intesti-
nal absorption (31) or eliminate toxic hydro-
phobic bile acids from the liver or reduce the
toxic effects of these hydrophobic com-
pounds on hepatocyte membranes (32,33).
UDCA may also reduce expression of class
II HLA inhibitors and interleukin and inter-
feron production, acting as an immunomodu-
lator (34), in addition to having the potential
to reduce reactive oxygen species (35,36).
In obese patients with NAFLD, triglycer-
ide accumulation in the liver is due to an
increased mobilization and availability of
free fatty acids from peripheral adipose tis-
sues, increased hepatic free fatty acids syn-
thesis and esterification and decreased ex-
port of triglycerides from the liver (37,38).
Oxidative stress or endotoxic cytokine-me-
diated injury may follow this fat accumula-
tion, leading to hepatic fibrosis and cirrhosis
(17,30,39).
When CT was used as a method of quan-
tification of the lipid content of the liver, no
significant differences were found between
results obtained at the beginning and at the
end of treatment in either group. Since this
evaluation was only performed again at the
end of the experiment, we may have missed
some modifications in this parameter during
the first two months of follow-up when the
biochemical response was maximal. How-
ever, due to the short time of follow-up and
to the fact that ALT levels were still signifi-
cantly reduced when CT was performed, it is
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more likely that such enzymatic alterations
observed in the treated group were not re-
lated to a reduction in hepatic lipid content.
Under these conditions, improvement in
hepatic enzyme levels in NAFLD could be
related to fat reduction in cell and mitochon-
drial membranes secondary to hydrophobic
toxic bile acids (32,33,40). It is also possible
that UDCA could reduce oxidative stress in
NAFLD due to an increase in hepatocyte
levels of glutathione and thiol-containing
proteins, as proposed by others (35).
The results of the present study suggest
that a CT scan is useful for the assessment of
the degree of liver steatosis and demonstrate
a transitory and significant effect of UDCA
on the reduction of hepatic enzyme levels in
patients with NAFLD. Such effect is not
related to modifications in liver fat content,
or in BMI. The exact mechanism by which
UDCA acts on NAFLD remains to be estab-
lished. It also remains to be ascertained
whether a sustained effect could be obtained
with higher and prolonged doses of UDCA,
as used by others (12).
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